In some aspects, the production platform CrisBioTM is similar to the egg-based production, but differs in its versatility. Eggs can be used only for viruses that replicate efficiently in them. Frequently, a single vaccine dose is obtained from a single egg (e.g. influenza vaccine). In contrast, the T. ni pupae may produce any recombinant subunit vaccine and dozens of vaccine doses can be produced by a single baculovirus infected pupa. CrisBioTM technology consist in a semi-automated process which facilitates scaling-up production. Several companies produce today their next generation vaccines by this technology.